ãžã§ã³ã§ãïŒãå¥åº·ããšãç ç©¶ãã®è©±ãå®ã¯ãšã£ãŠã身è¿ãªãã§ãïŒ
çãããããã«ã¡ã¯ïŒæ ãšæ®ãããæããããã©ã³ã©ã€ã¿ãŒããžã§ã³ã§ããä»åã¯ãæ®æ®µããŸãè§Šããªããå¥åº·ããšãç ç©¶ãã®äžçã®ã話ã§ããããããé£ãããâŠããšæã£ãããªãã倧äžå€«ïŒ 誰ã«ã§ãããªãã»ã©ïŒããšèãæã£ãŠããããããã«ããã¿ç ããŠã話ãããŸããã
å æ¥ãåãåå ããŠããããåœéçãªåŠäŒãããå¬ãããç¥ãããå±ããŸããããªããšãåã®çºè¡šãè³ãããã ãããã§ãïŒãISPOR 2025 Award Winnersããšããå èšäºã§ç޹ä»ãããŠããã®ã§ããããããäžäœã©ãããããšãªã®ããäžç·ã«èŠãŠãããŸãããã
ISPORïŒã€ã¹ãã¢ïŒã£ãŠãã©ããªãšããïŒ
ãŸããå èšäºã«åºãŠãããISPORããšããèšèãããã¯ãInternational Society for Pharmacoeconomics and Outcomes Researchãã®ç¥ã§ãæ¥æ¬èªã«ãããšãåœéå»è¬çµæžã»ã¢ãŠãã«ã ç ç©¶åŠäŒããšãªããŸããããŒããããã ãèããšããã£ã±ãã¡ãã£ãšé£ããæããŸãããã
ãã£ãšç°¡åã«èšããšãISPORã¯ãç æ°ã®æ²»çãäºé²ã«ããããéïŒçµæžïŒãšããã®æ²»çã§æ£è ãããã©ãã ãè¯ããªã£ããïŒã¢ãŠãã«ã ãã€ãŸãçµæïŒããäžçã®å°éå®¶ãéãŸã£ãŠç ç©¶ããŠããå Žæãã ãšæã£ãŠãã ããã
èããŠã¿ãŠãã ãããäŸãã°ã颚éªãæ²»ãè¬ã2çš®é¡ãããšããŸããçæ¹ã¯100åã§æ²»ããã©å°ãæéãããããããçæ¹ã¯1000åã ãã©ãããã«æ²»ã£ãŠä»äºã«æ©ã埩垰ã§ãããã©ã¡ããè¯ããã人ã«ãã£ãŠéããŸãããïŒ
ISPORã¯ããŸãã«ãããªãæ²»çã®è²»çšããšãæ²»çã®å¹æïŒæ£è ããã®å æ°åºŠåããçæŽ»ã®è³ªãªã©ïŒãã®ãã©ã³ã¹ããç§åŠçã«ã©ãè©äŸ¡ãããäžçªè¯ãã®ããç ç©¶ããŠããããšã£ãŠã倧åãªçµç¹ãªãã§ããããããããšã§ãéãããå»çè²»ãã©ãã«ã©ã䜿ãã®ãæ£è ããã«ãšã£ãŠããããŠç€ŸäŒã«ãšã£ãŠæãè¯ãã®ãããã³ããåŸãããšãã§ãããã§ãã
åã®åè³ç ç©¶ãäžäœäœããããïŒãæ²»çã®äŸ¡å€ããæž¬ãæ°ããç©å·®ã
ããŠããããªISPORã®2025幎ã®äŒè°ã§ãåã®çºè¡šããBest General Podiumããšããè³ãããã ããŸããïŒãPodium Presentationããšããã®ã¯ãå£äžã§çºè¡šãã圢åŒã®ããšãã€ãŸãã倧å¢ã®å°éå®¶ã®åã§ãåã®ç ç©¶å 容ãèªãããããšããããšãªãã§ãã
åã®ç ç©¶çºè¡šã®ã¿ã€ãã«ã¯ããQuantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resectionããšãããã®ãããããŸãé·ãåªæã®ããã§ããïŒç¬ïŒãäžã€ãã€çŽè§£ããŠãããŸãããã
- ãQuantifying Treatment ValueïŒæ²»ç䟡å€ã®å®éåïŒãïŒããã¯ããæ²»çã«ãéããããããšã«ãã£ãŠãã©ããããè¯ãçµæãåŸãããã®ãããã®ã䟡å€ããæ°åã§æž¬ãããšããèãæ¹ã§ããäŸãã°ãåã«ãåœã䌞ã³ããã ãã§ãªãããçæŽ»ã®è³ªãäžãã£ãããä»äºãã§ããããã«ãªã£ãããå®¶æãšéããæéãå¢ããããšãã£ããæ£è ããã®çæŽ»å šäœãžã®è¯ã圱é¿ãå«ããŠããã®äŸ¡å€ãç·åçã«è©äŸ¡ããããšãã詊ã¿ã§ãã
- ãAlternative Health Benefit MetricsïŒä»£æ¿çãªå¥åº·äžã®æ©æµã®æž¬å®ææšïŒãïŒããããæ°ããç©å·®ããã®éšåã§ããåŸæ¥ã®ãåœãã©ãã ã䌞ã³ãããã ãã§ãªãããã©ãã ãèŠçãªãéããããããã©ãã ãæ®æ®µã®ç掻ãéãããããªã©ãæ§ã ãªåŽé¢ããæ²»çã®æ©æµã枬ãããã®æ°ããæ¹æ³ãæ¢ã£ãŠãããã§ãã
- ãAdjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following ResectionïŒé«éœ¢ã®EGFRéºäŒåå€ç°éå°çްèèºããæ£è
ã«ãããè¡åŸè£å©ãªã·ã¡ã«ãããçæ³ïŒãïŒããã¯ãå
·äœçãªç
æ°ãšæ²»çæ³ã®è©±ã§ãã
- ãNSCLCãã¯ãéå°çްèèºããããšãããèºããã®çš®é¡ã®ã²ãšã€ã§ãã
- ãEGFR mutatedããšããã®ã¯ãèºããã®äžã§ãããã现èã®ç¹å®ã®ãã¹ã€ããããå£ããŠããã¿ã€ãã®ããšããEGFRããšããéºäŒåãå€ç°ããŠãããšããã®ã¹ã€ãããåžžã«ãªã³ã«ãªã£ãŠããŸãããã现èãå¢ãããããªããŸãããã®ãã¹ã€ããããçãæã¡ããæ²»çè¬ããããã§ãã
- ãOsimertinibïŒãªã·ã¡ã«ãããïŒãã¯ããã®ãã¹ã€ããããçãæã¡ãããããã°ããã现èãã¹ããŒãã«ãã£ã€ããææ°ã®è¬ãã®äžã€ã§ãã
- ãResectionïŒåé€ïŒãã¯ãæè¡ã§ãããç©ççã«åãé€ãããšã§ãã
- ãããŠããAdjuvantïŒè£å©çïŒããšããã®ã¯ãæè¡ã§ãããåãé€ããåŸã«ãã念ã®ãããåçºãé²ãããã«ããå°ãæ²»çãç¶ããããšããæå³åãã§ãã
<